Analytical Data
-
Gene name
MTA1
- Application
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8K4B0
-
Expression Region
Tyr6~Arg218
-
Molecular Weight
55kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MTA1 (Metastasis Associated Protein 1) is a protein that has gained significant attention in cancer research due to its pivotal role in tumor progression and metastasis. Studies have indicated that MTA1 is part of the NuRD (Nucleosome Remodeling and Deacetylase) complex, which is involved in chromatin remodeling and gene expression regulation. Its overexpression has been implicated in various malignancies, including breast, prostate, and colorectal cancers, making it a potential biomarker for cancer diagnosis and prognosis. Furthermore, MTA1 has been associated with the epithelial-to-mesenchymal transition (EMT), a critical process that enables cancer cells to acquire migratory and invasive properties. Research has also highlighted MTA1's involvement in drug resistance, underscoring its importance in therapeutic responses. Consequently, MTA1 is not only a promising target for novel therapeutic strategies but also serves as a key focus for understanding the molecular mechanisms underlying cancer metastasis. The characterization of MTA1 recombinant proteins aids in elucidating its biological functions and interactions, providing insights that could lead to innovative approaches for cancer treatment and management.
